STOCK TITAN
  1. Home
  2. News
  3. KOD

Kodiak Sciences Inc - KOD STOCK NEWS

Welcome to our dedicated news page for Kodiak Sciences (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kodiak Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kodiak Sciences's position in the market.

News
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Kodiak Sciences Inc. reported business highlights and financial results for the quarter and year ended December 31, 2023. The company aims to progress its three late-stage clinical assets into Phase 3 value inflection points. Dr. Victor Perlroth, CEO, highlighted the positive Phase 1 study results of KSI-501 in patients with diabetic macular edema, showing safety, tolerability, and visual acuity gains. Kodiak plans to advance KSI-501 and KSI-101 into Phase 3 pivotal studies, with tarcocimab being the most advanced program. The company's cash position is strong, with $285.5 million in cash and cash equivalents, expected to support operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.4%
Tags
earnings
-
News
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
Rhea-AI Summary
Kodiak Sciences Inc. (KOD) will report its fourth quarter and full-year 2023 financial results on March 28, 2024. The company focuses on developing therapeutics for retinal diseases. A conference call and webcast will discuss recent business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.01%
Tags
conferences earnings
-
News
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
Rhea-AI Summary
Kodiak Sciences Inc. announces the presentation of first-time results of the KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. The study focuses on the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME). The presentation will outline the potential of the KSI-501 program in treating retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
conferences earnings clinical trial
News
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Kodiak Sciences Inc. (Nasdaq: KOD) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024, to discuss their transformative therapeutics for retinal diseases. The presentation will be available via live webcast on Kodiak's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
-
News
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Kodiak Sciences Inc. (KOD) to present at 6th Annual Evercore ISI HealthCONx Conference, offering a live webcast of the presentation for replay. The biopharmaceutical company is focused on transformative therapeutics for retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
conferences
-
News
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Kodiak Sciences Inc. (Nasdaq: KOD) reported business highlights and financial results for the quarter ended September 30, 2023. The company announced promising results from its retinal disease prospects, including tarcocimab ABC and KSI-501 ABC, and detailed their plan to reboot the tarcocimab program. Additionally, the financial results reflected a positive cash position and a reduced net loss compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
earnings
News
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
Rhea-AI Summary
Kodiak Sciences Inc. announced that its Phase 3 GLOW study evaluating tarcocimab tedromer 5 mg in NPDR met its primary endpoint. The data showed significant improvement in diabetic eye disease status and prevention of sight-threatening complications. Kodiak plans to conduct one additional pivotal study with a commercial formulation of tarcocimab. The company believes it has sufficient capital to fund the development of its clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.56%
Tags
clinical trial
-
News
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
Rhea-AI Summary
Kodiak Sciences Inc (NASDAQ: KOD) will present data from the Phase 3 GLOW study of tarcocimab tedromer at the annual meeting of the American Academy of Ophthalmology (AAO). The study evaluates the efficacy of tarcocimab in patients with non-proliferative diabetic retinopathy. The primary endpoint is the proportion of patients with at least a 2-step improvement on the diabetic retinopathy severity scale. The secondary endpoint measures the proportion of patients with sight-threatening complications. Diabetic retinopathy affects 10 million out of 36 million American adults with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.01%
Tags
clinical trial
-
News
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
Rhea-AI Summary
Kodiak Sciences to present primary results from Phase 3 studies at Retina Society meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
conferences
News
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Summary
Kodiak Sciences to present at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences
Stock KOD logo
Kodiak Sciences Inc

Nasdaq:KOD

KOD Rankings

#3892 Ranked by Market Cap
#5318 Ranked by Stock Gains
N/A Ranked by Dividends

KOD Stock Data

231.56M
31.99M
5.66%
78.77%
4.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Palo Alto

About KOD

about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh